AMPH
Amphastar Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.18
−2.77%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 730.0M | 719.9M | 732.0M | 644.4M | 499.0M |
| Cost of Revenue | 381.9M | 363.8M | 358.1M | 293.3M | 250.1M |
| Gross Profit | 348.1M | 356.1M | 373.9M | 351.1M | 248.9M |
| Operating Expenses | |||||
| R&D Expense | 94.6M | 85.8M | 73.9M | 73.7M | 74.8M |
| SG&A Expense | 139.3M | 129.8M | 94.5M | 80.4M | 66.6M |
| General & Admin Expense | 92.2M | 85.9M | 56.7M | 51.5M | 45.1M |
| Selling & Marketing Expense | 47.0M | 43.9M | 37.8M | 28.9M | 21.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 233.8M | 215.7M | 168.4M | 154.1M | 141.4M |
| Cost and Expenses | 615.7M | 579.5M | 526.5M | 447.4M | 391.5M |
| Operating Income (EBIT) | 114.3M | 140.4M | 205.4M | 197.0M | 107.5M |
| Non-Operating | |||||
| Interest Income | 9.4M | 8.7M | 10.6M | 5.5M | 1.3M |
| Interest Expense | 26.1M | 25.5M | 30.3M | 27.2M | 1.8M |
| Net Interest Income | (16.8M) | (16.8M) | (19.7M) | (21.7M) | (525.0K) |
| Other Non-Op Income/Expense | (12.3M) | (16.8M) | (16.2M) | (27.6M) | 7.4M |
| Non-Operating Income (excl Interest) | (13.9M) | (8.7M) | (14.7M) | (1.5M) | (10.4M) |
| EBT (Pre-Tax Income) | 102.0M | 123.6M | 189.2M | 169.4M | 114.9M |
| Income Tax Expense | 23.5M | 25.5M | 29.7M | 31.8M | 23.5M |
| Bottom Line | |||||
| Net Income | 78.5M | 98.1M | 159.5M | 137.5M | 91.4M |
| Earnings from Cont. Ops | 78.5M | 98.1M | 159.5M | 137.5M | 91.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 78.5M | 98.1M | 159.5M | 137.5M | 91.4M |
| Per Share | |||||
| Basic EPS | $1.74 | $2.10 | $3.29 | $2.85 | $1.88 |
| Diluted EPS | $1.69 | $2.03 | $3.06 | $2.60 | $1.74 |
| Revenue Per Share | $16.73 | $15.40 | $15.11 | $13.35 | $10.28 |
| Shares | |||||
| Basic Shares Outstanding | 43.6M | 46.7M | 48.4M | 48.3M | 48.6M |
| Diluted Shares Outstanding | 44.2M | 48.2M | 52.1M | 53.0M | 52.4M |
| Profitability Metrics | |||||
| EBITDA | 174.8M | 212.3M | 277.3M | 240.3M | 146.2M |
| D&A | 46.6M | 63.2M | 57.2M | 41.8M | 28.3M |
| EBIT | 128.1M | 149.1M | 220.1M | 198.5M | 117.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026